 |
|
Risk Factors for the Rising Rates of Primary Liver Cancer in the United States
Hashem B. El-Serag, MD, MPH;
Andrew C. Mason, MD
Arch Intern Med. 2000;160:3227-3230.
Background A recent increase in the incidence of hepatocellular carcinoma was reported in the United States. The cause of this witnessed rise remains unknown.
Methods We examined the temporal changes in both age-specific and age-standardized hospitalization rates of primary liver cancer associated with hepatitis C, hepatitis B, and alcoholic cirrhosis in the Department of Veterans Affairs Medical Center's Patient Treatment File.
Results A total of 1605 patients were diagnosed with primary liver cancer between 1993 and 1998. The overall age-adjusted proportional hospitalization rate for primary liver cancer increased from 36.4 per 100,000 (95% confidence interval [CI], 34.0-38.9) between 1993 and 1995 to 47.5 per 100,000 (95% CI, 44.6-50.1) between 1996 and 1998. There was a 3-fold increase in the age-adjusted rates for primary liver cancer associated with hepatitis C virus, from 2.3 per 100,000 (95% CI, 1.8-3.0) between 1993 and 1995 to 7.0 per 100,000 (95% CI, 5.9-8.1) between 1996 and 1998. Concomitant with this rise, the age-specific rates for primary liver cancer associated with hepatitis C also shifted toward younger patients. During the same periods, the age-adjusted rates for primary liver cancer associated with either hepatitis B virus (2.2 vs 3.1 per 100,000) or alcoholic cirrhosis (8.4 vs 9.1 per 100,000) remained stable. The rates for primary liver cancer without risk factors also remained without a statistically significant change, from 17.5 (95% CI, 15.8-19.1) between 1993 and 1995 to 19.0 per 100,000 (95% CI, 17.3-20.7) between 1996 and 1998.
Conclusions Hepatitis C virus infection accounts for most of the increase in the number of cases of primary liver cancer among US veterans. The rates of primary liver cancer associated with alcoholic cirrhosis and hepatitis B virus infection have remained stable.
From the Gastroenterology and Health Services Sections, Houston Department of Veterans Affairs Medical Center and Baylor College of Medicine, Houston, Tex (Dr El-Serag); and the Department of Gastroenterology, University of New Mexico, Albuquerque (Dr Mason).
RELATED ARTICLE
Archives of Internal Medicine Reader's Choice: Continuing Medical Education
Arch Intern Med. 2000;160(21):3332-3333.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Declining Incidence of Hepatocellular Carcinoma in Osaka, Japan, from 1990 to 2003
Tanaka et al.
ANN INTERN MED 2008;148:820-826.
ABSTRACT
| FULL TEXT
Epidemiology of Hepatocellular Carcinoma in Hispanics in the United States
El-Serag et al.
Arch Intern Med 2007;167:1983-1989.
ABSTRACT
| FULL TEXT
Recurrence of Hepatocellular Carcinoma After Liver Transplantation: Patterns and Prognostic Factors Based on Clinical and Radiologic Features
Kim et al.
Am. J. Roentgenol. 2007;189:352-358.
ABSTRACT
| FULL TEXT
The Use of Epigenetic Biomarkers for Preclinical Detection of Hepatocellular Carcinoma: Potential for Noninvasive Screening of High-Risk Populations
Rivenbark and Coleman
Clin. Cancer Res. 2007;13:2309-2312.
FULL TEXT
Activation of the hedgehog pathway in human hepatocellular carcinomas
Huang et al.
Carcinogenesis 2006;27:1334-1340.
ABSTRACT
| FULL TEXT
Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study
Davila et al.
Gut 2005;54:533-539.
ABSTRACT
| FULL TEXT
Prediction of Liver Fibrosis and Cirrhosis in Chronic Hepatitis B Infection by Serum Proteomic Fingerprinting: A Pilot Study
Poon et al.
Clin. Chem. 2005;51:328-335.
ABSTRACT
| FULL TEXT
ALCOHOL AND CANCER
Poschl and Seitz
Alcohol Alcohol 2004;39:155-165.
ABSTRACT
| FULL TEXT
The Continuing Increase in the Incidence of Hepatocellular Carcinoma in the United States: An Update
El-Serag et al.
ANN INTERN MED 2003;139:817-823.
ABSTRACT
| FULL TEXT
Incidence and Cofactors of Hepatitis C Virus-related Hepatocellular Carcinoma: A Prospective Study of 12,008 Men in Taiwan
Sun et al.
Am J Epidemiol 2003;157:674-682.
ABSTRACT
| FULL TEXT
Phase II Trial of Systemic Continuous Fluorouracil and Subcutaneous Recombinant Interferon Alfa-2b for Treatment of Hepatocellular Carcinoma
Patt et al.
JCO 2003;21:421-427.
ABSTRACT
| FULL TEXT
Imaging in the Diagnosis, Staging, Treatment, and Surveillance of Hepatocellular Carcinoma
Szklaruk et al.
Am. J. Roentgenol. 2003;180:441-454.
FULL TEXT
Inaugural Article: A comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades
Tanaka et al.
Proc. Natl. Acad. Sci. USA 2002;99:15584-15589.
ABSTRACT
| FULL TEXT
Identify Metastasis-associated Genes in Hepatocellular Carcinoma through Clonality Delineation for Multinodular Tumor
Cheung et al.
Cancer Res. 2002;62:4711-4721.
ABSTRACT
| FULL TEXT
Cocarcinogenic effects of alcohol in hepatocarcinogenesis
Stickel et al.
Gut 2002;51:132-139.
ABSTRACT
| FULL TEXT
Phase II Trial of Cisplatin, Interferon {alpha}-2b, Doxorubicin, and 5-Fluorouracil for Biliary Tract Cancer
Patt et al.
Clin. Cancer Res. 2001;7:3375-3380.
ABSTRACT
| FULL TEXT
Nonresponse to Interferon in Chronic Hepatitis C: Re-treatment Redux
Koff
JAMA 2001;285:212-214.
FULL TEXT
|
